CN119136841A - 抗CanAg抗体偶联物 - Google Patents

抗CanAg抗体偶联物 Download PDF

Info

Publication number
CN119136841A
CN119136841A CN202380037771.5A CN202380037771A CN119136841A CN 119136841 A CN119136841 A CN 119136841A CN 202380037771 A CN202380037771 A CN 202380037771A CN 119136841 A CN119136841 A CN 119136841A
Authority
CN
China
Prior art keywords
cancer
adc
antibody
antibody conjugate
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037771.5A
Other languages
English (en)
Chinese (zh)
Inventor
珍妮·瑟尔韦
丹尼尔·约翰·威廉姆森
朱塔·德克特
贾斯蒂娜·米斯利维
罗伯特·卢茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icosta Medical Co ltd
Original Assignee
Icosta Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icosta Medical Co ltd filed Critical Icosta Medical Co ltd
Publication of CN119136841A publication Critical patent/CN119136841A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202380037771.5A 2022-03-04 2023-03-06 抗CanAg抗体偶联物 Pending CN119136841A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2203070.4A GB202203070D0 (en) 2022-03-04 2022-03-04 Anti-canag antibody conjugate
GB2203070.4 2022-03-04
PCT/GB2023/050522 WO2023166322A1 (en) 2022-03-04 2023-03-06 Anti-canag antibody conjugate

Publications (1)

Publication Number Publication Date
CN119136841A true CN119136841A (zh) 2024-12-13

Family

ID=81175257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037771.5A Pending CN119136841A (zh) 2022-03-04 2023-03-06 抗CanAg抗体偶联物

Country Status (9)

Country Link
US (1) US20250213711A1 (https=)
EP (1) EP4486392A1 (https=)
JP (1) JP2025509152A (https=)
KR (1) KR20240163656A (https=)
CN (1) CN119136841A (https=)
AU (1) AU2023229192A1 (https=)
GB (1) GB202203070D0 (https=)
IL (1) IL315428A (https=)
WO (1) WO2023166322A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
GB202313214D0 (en) * 2023-08-30 2023-10-11 Iksuda Therapeutics Ltd Co-administration of antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045348T2 (hu) 2011-05-08 2019-12-30 Legochem Biosciences Inc Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
MX2019011655A (es) * 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
EP3950061A4 (en) * 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE

Also Published As

Publication number Publication date
AU2023229192A1 (en) 2024-09-12
EP4486392A1 (en) 2025-01-08
IL315428A (en) 2024-11-01
KR20240163656A (ko) 2024-11-19
WO2023166322A1 (en) 2023-09-07
US20250213711A1 (en) 2025-07-03
JP2025509152A (ja) 2025-04-11
GB202203070D0 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
CA3093327C (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
CN105980411B (zh) 抗体-药物缀合物和免疫毒素
CN119136841A (zh) 抗CanAg抗体偶联物
US10562977B2 (en) Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
CN105979971B (zh) 抗体-药物缀合物和免疫毒素
JP7057391B2 (ja) タンパク薬物複合体で使用するためのリンカーに関連する材料および方法
JP7846624B2 (ja) ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート
KR20250137203A (ko) 항체 약물 접합체
JP2019524845A (ja) セコ−シクロプロパピロロインドール化合物、その抗体−薬物コンジュゲート、ならびに製造および使用方法
US20230201366A1 (en) Anti-psma conjugates
JP2023546293A (ja) 抗ｃｓｐｇ４結合剤、そのコンジュゲートおよびその使用方法
CN121793986A (zh) 抗体-药物缀合物的联合施用
WO2024013520A1 (en) Folate receptor targeting antibody-drug conjugates
NZ728857B2 (en) Materials and methods relating to linkers for use in protein drug conjugates
BR112016018005B1 (pt) Conjugados anticorpo-droga e imunotoxinas
HK1241745B (en) Materials and methods relating to linkers for use in protein drug conjugates
HK1241745A1 (en) Materials and methods relating to linkers for use in protein drug conjugates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination